UniQure CEO Soland makes a quick ex­it as ex­ecs ham­mer out a new strat­e­gy

Nine months af­ter land­ing a new job as CEO of the Dutch gene ther­a­py biotech uniQure, Dan Soland abrupt­ly quit on Thurs­day, say­ing the un­ex­pect­ed move was due “sole­ly” to fam­i­ly rea­sons. And the com­pa­ny says it doesn’t plan on re­plac­ing him im­me­di­ate­ly, pre­fer­ring to wait un­til af­ter it im­ple­ments a new cor­po­rate strat­e­gy now in the works.

CFO Matthew Ka­pus­ta will now take the helm as in­ter­im CEO, with for­mer pres­i­dent Philip Ast­ley-Sparke step­ping up as chair­man. In a state­ment, Ast­ley-Sparke praised Ka­pus­ta for his work “guid­ing an on­go­ing, com­pre­hen­sive strate­gic plan­ning process.”

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.